Diligence memo · auto-generated · as of July 2, 2026
Opus Genetics Inc.
Opus Genetics Inc. looks fair against its niche peers and is at-risk on financing cadence.
Businessfiled
Opus Genetics Inc. operates in Biotechnology, based in DURHAM.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Opus Genetics Inc. has raised $14M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $9.5M on 2021-08-05.
Most recent recorded round closed around 2023-06-05.
Valuation (modeled)modeled
Provath models Opus Genetics Inc. at approximately $40M (range $4.9M–$110M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.89× the median modeled value of Series A Biotechnology companies in 2022–2024 (303 peers) — value vs value, same stage and era. Within the normal band (89% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 22 months.
Last raise 3.1 yr ago; this sector typically re-raises about every 14 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round was 2.1× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 62% of Biotechnology peers (4293 compared).
Modeled value ranks above 40% of those peers.
Closest niche peers: GeoVax Labs, Inc., Cellinfinity Bio Holding Company, LLC, Adient Medical, Inc., Entegrion Inc, BCD Bioscience, Inc..
Peoplefiled
4 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.